GeneDx Holdings Corp. Class A Common Stock WGS

GeneDx Holdings Corp. es una empresa de genómica. La empresa se enfoca en proporcionar información de salud personalizada y accionable para informar el diagnóstico, dirigir el tratamiento y mejorar el descubrimiento de medicamentos. Los segmentos de la empresa son GeneDx y Legacy Sema4. El segmento de GeneDx proporciona principalmente diagnósticos de enfermedades pediátricas y raras con un enfoque en secuenciación de exoma completo y genoma, y, en menor medida, servicios de datos e información. GeneDx utiliza un portafolio integrado de procesos de laboratorio, herramientas de software y capacidades informáticas para procesar muestras que contienen ácido desoxirribonucleico (ADN), analizar información sobre variaciones genéticas específicas del paciente y generar informes de prueba para los médicos y sus pacientes. GeneDx proporciona una variedad de pruebas diagnósticas genéticas, soluciones de cribado e información. El segmento de diagnóstico Legacy Sema4 proporciona pruebas diagnósticas y de cribado en salud reproductiva y de la mujer y oncología somática.

WGS hizo una agrupación de acciones (split inverso) de 1:33 el 4 de mayo de 2023: cada 33 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 14 sept

  Should You Invest in the State Street SPDR S&P Health Care Services ETF (XHS)?

  The State Street SPDR S&P Health Care Services ETF (XHS) is a passively managed healthcare services sector ETF with low costs (0.35% expense ratio) and solid year-to-date performance of 27.29%. The fund holds about 62 healthcare companies with a medium risk profile (beta of 0.93) and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable option for investors seeking diversified healthcare sector exposure.

  

• GlobeNewswire Inc. 1 ago

  WGS DEADLINE MONDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 3 Deadline in Securities Class Action - WGS

  A securities class action lawsuit has been filed against GeneDx Holdings Corp. (WGS) for allegedly making false statements about the Fabric acquisition's impact on the company's financials and operational efficiencies. The lawsuit claims defendants knew of significant problems with Fabric's viability that would negatively impact the business. Investors with losses exceeding $100K are encouraged to join the class action before the August 3, 2026 lead plaintiff deadline.

  

• GlobeNewswire Inc. 1 ago

  מועד אחרון לתביעה הייצוגית נגד ב-WGS ביום שני: רוזן, יועץ מהימן למשקיעים, קורא למשקיעי GeneDx Holdings Corp שספגו הפסדים העולים על 100,000 דולר לקבל ייצוג משפטי לפני המועד החשוב ב-3 באוגוסט במסגרת תביעה ייצוגית בניירות ערך – WGS

  Rosen Law Firm announces a securities class action lawsuit against GeneDx Holdings Corp (WGS) for alleged false statements regarding the Fabric acquisition. The firm claims GeneDx made misleading statements about cost reduction and operational synergies that never materialized, causing investor losses. The deadline to join the class action is August 3, 2026.

  

• GlobeNewswire Inc. 31 jul

  MONDAY DEADLINE: GeneDx Holdings Corp. (WGS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

  GeneDx Holdings Corp. (WGS) investors with substantial losses have until August 3, 2026 to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The lawsuit alleges that GeneDx made false and misleading statements regarding the viability of its Fabric Genomics acquisition. GeneDx's stock dropped over 49% on May 4, 2026 after revealing a significant drop in adjusted gross margin from 74% to 69%, reduced earnings projections, and a $31.3 million impairment loss directly attributable to Fabric Genomics.

  

• GlobeNewswire Inc. 30 jul

  GeneDx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against GeneDx Holdings Corp. - WGS

  GeneDx Holdings Corp. faces a securities class action lawsuit for failing to disclose material information between April 16, 2025 and May 4, 2026. The company reported a significant drop in adjusted gross margin from 74% to 69%, missed revenue estimates, lowered full-year guidance from $540-$550M to $475-$490M, and took a $31.2M impairment loss on its Fabric Genomics acquisition. GeneDx shares fell 49.2% on the announcement. Investors with losses exceeding $100,000 have until August 3, 2026 to file lead plaintiff applications.